Anavex terminates CEO Christopher Missling for cause; appoints Terrie Kellmeyer as interim CEO

ANAVEX LIFE SCIENCES CORP.

Christopher Missling terminated as CEO for cause effective April 30, 2026; Board requested his resignation.
Terrie Kellmeyer appointed Interim CEO effective May 4, 2026; former SVP Clinical Development at Anavex.
Kellmeyer's compensation: $500k base salary, 30% bonus, $150k signing bonus, 200k stock options pending.
Company expects to file Form 12b-25 to extend deadline for Q2 2026 10-Q (quarter ended March 31, 2026).
Conference call to discuss Q2 2026 financial results and filing to be scheduled later.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Terrie Kellmeyer

Interim Chief Executive Officer

AVXL · ANAVEX LIFE SCIENCES CORP.

Effective: 2026-05-04
Filed: May 6, 2026, 7:59 PM ET

On May 4, 2026, the Board appointed Terrie Kellmeyer, PhD as the Company's Interim Chief Executive Officer.

Departed

Christopher Missling

Chief Executive Officer

AVXL · ANAVEX LIFE SCIENCES CORP.

Effective: 2026-04-30
Successor: Terrie Kellmeyer
Filed: May 6, 2026, 7:59 PM ET

On April 30, 2026, a special committee (the "Special Committee") composed of independent directors of the Board of Directors (the "Board") of Anavex Life Sciences Corp. (the "Company") terminated the employment of Christopher Missling, PhD as the Company's Chief Executive Officer for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between Dr. Missling and the Company, as amended and restated), effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Terrie Kellmeyer was appointed as Interim Chief Executive Officer at ANAVEX LIFE SCIENCES CORP..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

On May 4, 2026, the Board appointed Terrie Kellmeyer, PhD as the Company's Interim Chief Executive Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Missling was terminated as Chief Executive Officer at ANAVEX LIFE SCIENCES CORP..

Action: terminated
Role: Chief Executive Officer

Exact text from the filing

On April 30, 2026, a special committee (the "Special Committee") composed of independent directors of the Board of Directors (the "Board") of Anavex Life Sciences Corp. (the "Company") terminated the employment of Christopher Missling, PhD as the Company's Chief Executive Officer for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between Dr. Missling and the Company, as amended and restated), effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy.

View on SEC.gov

ANAVEX LIFE SCIENCES CORP. filing history →

Source: SEC EDGAR

accession 0001731122-26-000678

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.